GSK India Targets ₹8,000 Crore Revenue Milestone by FY30
· Business · Business Standard, Economic Times
GlaxoSmithKline Pharmaceuticals India aims to double its annual revenue to ₹8,000 crore by the end of the 2030 financial year. Managing Director Bhushan Akshikar stated the company plans to achieve this growth by expanding its presence in key therapeutic segments, including vaccines and specialty medicines. The strategy involves strengthening the company's portfolio in areas such as respiratory, shingles, and meningitis vaccines. GSK India intends to leverage its existing distribution network to increase market penetration across the country. The company's leadership remains focused on long-term growth despite competitive pressures in the domestic pharmaceutical sector.
Why it matters
This growth target signals a significant expansion for one of India's major multinational pharmaceutical players, potentially increasing the availability of specialized vaccines and treatments for Indian patients.
Read the original report — Business Standard
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.